1
|
Echeverría E, Ripoll S, Fabián L, Shayo C, Monczor F, Fernández NC. Novel inhibitors of phosphorylation independent activity of GRK2 modulate cAMP signaling. Pharmacol Res Perspect 2022; 10:e00913. [PMID: 35184416 PMCID: PMC8858223 DOI: 10.1002/prp2.913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 12/20/2021] [Accepted: 12/21/2021] [Indexed: 11/10/2022] Open
Affiliation(s)
- Emiliana Echeverría
- Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
- Instituto de Investigaciones Farmacológicas (ININFA‐UBA‐CONICET) Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
| | - Sonia Ripoll
- Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
- Instituto de Investigaciones Farmacológicas (ININFA‐UBA‐CONICET) Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
| | - Lucas Fabián
- Instituto de Química y Metabolismo del Fármaco (IQUIMEFA‐UBA‐CONICET) Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
| | - Carina Shayo
- Laboratorio de Patología y Farmacología Molecular Instituto de Biología y Medicina Experimental (IByME) CONICET Buenos Aires Argentina
| | - Federico Monczor
- Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
- Instituto de Investigaciones Farmacológicas (ININFA‐UBA‐CONICET) Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
| | - Natalia C. Fernández
- Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
- Instituto de Investigaciones Farmacológicas (ININFA‐UBA‐CONICET) Facultad de Farmacia y Bioquímica Universidad de Buenos Aires Buenos Aires Argentina
| |
Collapse
|
2
|
Burghi V, Echeverría EB, Zappia CD, Díaz Nebreda A, Ripoll S, Gómez N, Shayo C, Davio CA, Monczor F, Fernández NC. Biased agonism at histamine H 1 receptor: Desensitization, internalization and MAPK activation triggered by antihistamines. Eur J Pharmacol 2021; 896:173913. [PMID: 33508282 DOI: 10.1016/j.ejphar.2021.173913] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 01/18/2021] [Accepted: 01/21/2021] [Indexed: 11/19/2022]
Abstract
Histamine H1 receptor ligands used clinically as antiallergics rank among the most widely prescribed and over-the-counter drugs in the world. They exert the therapeutic actions by blocking the effects of histamine, due to null or negative efficacy towards Gαq-phospholipase C (PLC)-inositol triphosphates (IP3)-Ca2+ and nuclear factor-kappa B cascades. However, there is no information regarding their ability to modulate other receptor responses. The aim of the present study was to investigate whether histamine H1 receptor ligands could display positive efficacy concerning receptor desensitization, internalization, signaling through Gαq independent pathways or even transcriptional regulation of proinflammatory genes. While diphenhydramine, triprolidine and chlorpheniramine activate ERK1/2 (extracellular signal-regulated kinase 1/2) pathway in A549 cells, pre-treatment with chlorpheniramine or triprolidine completely desensitize histamine H1 receptor mediated Ca2+ response, and both diphenhydramine and triprolidine lead to receptor internalization. Unlike histamine, histamine H1 receptor desensitization and internalization induced by antihistamines prove to be independent of G protein-coupled receptor kinase 2 (GRK2) phosphorylation. Also, unlike the reference agonist, the recovery of the number of cell-surface histamine H1 receptors is a consequence of de novo synthesis. On the other hand, all of the ligands lack efficacy regarding cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8) mRNA regulation. However, a prolonged exposure with each of the antihistamines impaires the increase in COX-2 and IL-8 mRNA levels induced by histamine, even after ligand removal. Altogether, these findings demonstrate the biased nature of histamine H1 receptor ligands contributing to a more accurate classification, and providing evidence for a more rational and safe use of them.
Collapse
Affiliation(s)
- Valeria Burghi
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Emiliana B Echeverría
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Carlos D Zappia
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Antonela Díaz Nebreda
- Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental (IByME-CONICET), Buenos Aires, Argentina
| | - Sonia Ripoll
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Natalia Gómez
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Carina Shayo
- Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental (IByME-CONICET), Buenos Aires, Argentina
| | - Carlos A Davio
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Federico Monczor
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Natalia C Fernández
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina; Instituto de Investigaciones Farmacológicas (ININFA, UBA, CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
| |
Collapse
|
3
|
Burghi V, Echeverría EB, Sosa MH, Quiroga DT, Muñoz MC, Davio C, Monczor F, Fernández NC, Dominici FP. Participation of Gα i-Adenylate Cyclase and ERK1/2 in Mas Receptor Signaling Pathways. Front Pharmacol 2019; 10:146. [PMID: 30853914 PMCID: PMC6395383 DOI: 10.3389/fphar.2019.00146] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Accepted: 02/06/2019] [Indexed: 12/21/2022] Open
Abstract
The MasR receptor (MasR) is an orphan G protein-coupled receptor proposed as a candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang-(1–7) protective axis of renin-angiotensin system. This receptor has been suggested to participate in several physiological processes including cardio- and reno-protection and regulation of the central nervous system function. Although the knowledge of the signaling mechanisms associated with MasR is essential for therapeutic purposes, these are still poorly understood. Accordingly, in the current study we aimed to characterize the signaling pathways triggered by the MasR. To do that, we measured cAMP and Ca2+ levels in both naïve and MasR transfected cells in basal conditions and upon incubation with putative MasR ligands. Besides, we evaluated activation of ERK1/2 by Ang-(1–7) in MasR transfected cells. Results indicated the existence of a high degree of MasR constitutive activity toward cAMP modulation. This effect was not mediated by the PDZ-binding motif of the MasR but by receptor coupling to Gαi-adenylyl cyclase signaling pathway. Incubation of MasR transfected cells with Ang-(1–7) or the synthetic ligand AVE 0991 amplified MasR negative modulation of cAMP levels. On the other hand, we provided evidence for lack of MasR-associated modulation of Ca2+ levels by Ang-(1–7). Finally, it was determined that the MasR attenuated Ang-(1–7)-induced ERK1/2 phosphorylation mediated by AT1R. We provided further characterization of MasR signaling mechanisms regarding its constitutive activity and response to putative ligands. This information could prove useful to better describe MasR physiological role and development of therapeutic agents that could modulate its action.
Collapse
Affiliation(s)
- Valeria Burghi
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Emiliana B Echeverría
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Máximo H Sosa
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Diego T Quiroga
- Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Buenos Aires, Argentina
| | - Marina C Muñoz
- Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Buenos Aires, Argentina
| | - Carlos Davio
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Federico Monczor
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Natalia C Fernández
- Facultad de Farmacia y Bioquímica, Instituto de Investigaciones Farmacológicas (ININFA), Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
| | - Fernando P Dominici
- Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Buenos Aires, Argentina
| |
Collapse
|
4
|
Alonso N, Zappia CD, Cabrera M, Davio CA, Shayo C, Monczor F, Fernández NC. Physiological implications of biased signaling at histamine H2 receptors. Front Pharmacol 2015; 6:45. [PMID: 25805997 PMCID: PMC4354273 DOI: 10.3389/fphar.2015.00045] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 02/20/2015] [Indexed: 12/25/2022] Open
Abstract
Histamine mediates numerous functions acting through its four receptor subtypes all belonging to the large family of seven transmembrane G-protein coupled receptors. In particular, histamine H2 receptor (H2R) is mainly involved in gastric acid production, becoming a classic pharmacological target to treat Zollinger–Ellison disease and gastric and duodenal ulcers. H2 ligands rank among the most widely prescribed and over the counter-sold drugs in the world. Recent evidence indicate that some H2R ligands display biased agonism, selecting and triggering some, but not all, of the signaling pathways associated to the H2R. The aim of the present work is to study whether famotidine, clinically widespread used ligand acting at H2R, exerts biased signaling. Our findings indicate that while famotidine acts as inverse agonist diminishing cAMP basal levels, it mimics the effects of histamine and the agonist amthamine concerning receptor desensitization and internalization. Moreover, the treatment of HEK293T transfected cells with any of the three ligands lead to a concentration dependent pERK increment. Similarly in AGS gastric epithelial cells, famotidine treatment led to both, the reduction in cAMP levels as well as the increment in ERK phosphorylation, suggesting that this behavior could have pharmacological relevant implications. Based on that, histidine decarboxylase expression was studied by quantitative PCR in AGS cells and its levels were increased by famotidine as well as by histamine and amthamine. In all cases, the positive regulation was impeded by the MEK inhibitor PD98059, indicating that biased signaling toward ERK1/2 pathway is the responsible of such enzyme regulation. These results support that ligand bias is not only a pharmacological curiosity but has physiological and pharmacological implications on cell metabolism.
Collapse
Affiliation(s)
- Natalia Alonso
- Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina
| | - Carlos D Zappia
- Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina, ; Laboratorio de Farmacología de Receptores, Cátedra de Química Medicinal, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Buenos Aires, Argentina
| | - Maia Cabrera
- Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina, ; Laboratorio de Farmacología de Receptores, Cátedra de Química Medicinal, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Buenos Aires, Argentina
| | - Carlos A Davio
- Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina, ; Laboratorio de Farmacología de Receptores, Cátedra de Química Medicinal, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Buenos Aires, Argentina ; Instituto de Investigaciones Farmacológicas - Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina
| | - Carina Shayo
- Laboratorio de Patología y Farmacología Molecular, Instituto de Biología y Medicina Experimental Buenos Aires, Argentina ; Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina
| | - Federico Monczor
- Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina, ; Laboratorio de Farmacología de Receptores, Cátedra de Química Medicinal, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Buenos Aires, Argentina
| | - Natalia C Fernández
- Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires, Argentina, ; Laboratorio de Farmacología de Receptores, Cátedra de Química Medicinal, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires Buenos Aires, Argentina
| |
Collapse
|